GTx Inc. (GTXI)

5.92
0.07 1.25
NASDAQ : Health Technology
Prev Close 5.99
Open 5.99
Day Low/High 5.86 / 6.00
52 Wk Low/High 4.86 / 179.20
Volume 31.97K
Avg Volume 361.80K
Exchange NASDAQ
Shares Outstanding 24.05M
Market Cap 28.86M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Lifshitz & Miller LLP Announces Investigation Of Amarin Corporation Plc, Clementia Pharmaceuticals Inc., CVS Health Corporation, Diplomat Pharmacy, Inc., GTx, Inc., Multi-Color Corporation, Osiris Therapeutics, Inc., And The Kraft Heinz Company

Lifshitz & Miller LLP Announces Investigation Of Amarin Corporation Plc, Clementia Pharmaceuticals Inc., CVS Health Corporation, Diplomat Pharmacy, Inc., GTx, Inc., Multi-Color Corporation, Osiris Therapeutics, Inc., And The Kraft Heinz Company

NEW YORK, March 22, 2019 /PRNewswire/ -- Amarin Corporation plc (AMRN) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that Amarin administered an active agent to their placebo group during...

GTX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger Of GTx, Inc. - GTXI

GTX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger Of GTx, Inc. - GTXI

NEW ORLEANS, March 11, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.

GTx Reports Third Quarter 2018 Financial Results And Provides Corporate Update

GTx Reports Third Quarter 2018 Financial Results And Provides Corporate Update

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the third quarter ended September 30, 2018, and provided a corporate update.

GTx Announces Top-Line Results From Placebo-Controlled ASTRID Trial Of Enobosarm In Women With Stress Urinary Incontinence

GTx Announces Top-Line Results From Placebo-Controlled ASTRID Trial Of Enobosarm In Women With Stress Urinary Incontinence

GTx, Inc. (Nasdaq: GTXI) today announced that the ASTRID Trial, a Phase 2 double-blind, placebo-controlled clinical trial of orally-administered enobosarm (3 mg or 1 mg) in post-menopausal women with stress urinary incontinence (SUI), did not achieve...

GTx, Inc. To Participate In The Baird 2018 Global Healthcare Conference

GTx, Inc. To Participate In The Baird 2018 Global Healthcare Conference

GTx, Inc. (Nasdaq: GTXI) today announced that Robert J.

GTx Provides Corporate Update And Reports Second Quarter 2018 Financial Results

GTx Provides Corporate Update And Reports Second Quarter 2018 Financial Results

GTx, Inc. (Nasdaq:GTXI) today reported financial results for the second quarter ended June 30, 2018 and highlighted recent accomplishments and upcoming milestones.

GTx Added To The Russell 3000® Index

GTx Added To The Russell 3000® Index

GTx, Inc. (Nasdaq: GTXI) today announced that it has been added to the Russell 3000® Index as part of the Russell U.

GTx Updates Phase 2 Enobosarm Clinical Trial Results In Stress Urinary Incontinence At 2018 AUA Annual Meeting

GTx Updates Phase 2 Enobosarm Clinical Trial Results In Stress Urinary Incontinence At 2018 AUA Annual Meeting

GTx, Inc. (Nasdaq: GTXI) today released additional data supporting the durability of the response to a 12-week treatment with enobosarm 3 mg in an open-label, Phase 2 proof-of-concept clinical trial evaluating enobosarm in postmenopausal women with stress...

GTx Provides Corporate Update And Reports First Quarter 2018 Financial Results

GTx Provides Corporate Update And Reports First Quarter 2018 Financial Results

GTx, Inc. (Nasdaq:GTXI) today reported financial results for the first quarter ended March 31, 2018 and highlighted recent accomplishments and upcoming milestones.

Small-Cap Stocks Are Doing Something They Haven't Done Consistently in 3 Years

Small-Cap Stocks Are Doing Something They Haven't Done Consistently in 3 Years

Small-cap stocks have finally jumped back to life on prospects for a strong U.S. economy this year. What trade war?

GTx Provides Corporate Update And Reports Fourth Quarter And Full Year 2017 Financial Results

GTx Provides Corporate Update And Reports Fourth Quarter And Full Year 2017 Financial Results

GTx, Inc. (Nasdaq:GTXI) today reported financial results for the fourth quarter and year ended December 31, 2017 and highlighted recent accomplishments and upcoming milestones.

GTx Announced New Data Demonstrating Enobosarm's Potential To Treat Stress Urinary Incontinence At SUFU 2018

GTx Announced New Data Demonstrating Enobosarm's Potential To Treat Stress Urinary Incontinence At SUFU 2018

GTx, Inc. (Nasdaq:GTXI) today announced additional results from a Phase 2 proof-of-concept clinical trial of 3 mg enobosarm administered orally in postmenopausal women with stress urinary incontinence (SUI), including...

GTx Phase 2 Enobosarm Clinical Trial Results In Stress Urinary Incontinence Accepted For Podium Presentation At SUFU

GTx Phase 2 Enobosarm Clinical Trial Results In Stress Urinary Incontinence Accepted For Podium Presentation At SUFU

GTx, Inc. (Nasdaq: GTXI) today announced the acceptance of an abstract on clinical results from an ongoing, open-label, Phase 2 proof-of-concept clinical trial evaluating enobosarm 3 mg in postmenopausal women with stress...

GTx Provides Corporate Update And Reports Third Quarter 2017 Financial Results

GTx Provides Corporate Update And Reports Third Quarter 2017 Financial Results

GTx, Inc. (Nasdaq:GTXI) today reported financial results for the third quarter of 2017 and highlighted recent accomplishments and upcoming milestones.

GTx, Inc. To Participate In The Stifel 2017 Healthcare Conference

GTx, Inc. To Participate In The Stifel 2017 Healthcare Conference

GTx, Inc. (Nasdaq: GTXI) today announced that Robert J.

GTx Announces Closing Of $48.5 Million Private Placement

GTx Announces Closing Of $48.5 Million Private Placement

GTx, Inc. (NASDAQ: GTXI) today announced that it has closed the previously-announced private placement of its common stock and warrants to purchase its common stock.

GTx Announces $48.5 Million Private Placement

GTx Announces $48.5 Million Private Placement

GTx, Inc. (NASDAQ: GTXI) today announced that it has entered into a definitive securities purchase agreement for the sale of its common stock and warrants to purchase common stock in a private placement that is...

GTx Announces Webcast Of Corporate Presentation At The 2017 Cantor Fitzgerald Global Healthcare Conference

GTx Announces Webcast Of Corporate Presentation At The 2017 Cantor Fitzgerald Global Healthcare Conference

GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on September 27, 2017, at the 2017 Cantor Fitzgerald Global Healthcare Conference in New York City.

GTx To Host Key Opinion Leader Luncheon On The Topic Of Stress Urinary Incontinence On September 28th In New York City

GTx To Host Key Opinion Leader Luncheon On The Topic Of Stress Urinary Incontinence On September 28th In New York City

GTx, Inc. (Nasdaq: GTXI) today announced that it will be hosting and simultaneously webcasting a Key Opinion Leader (KOL) luncheon meeting on the topic of Stress Urinary Incontinence (SUI) on Thursday, September 28 th in...

GTx Announces Positive Results From Enobosarm Phase 2 Proof-of-Concept Clinical Trial In Women With Stress Urinary Incontinence

GTx Announces Positive Results From Enobosarm Phase 2 Proof-of-Concept Clinical Trial In Women With Stress Urinary Incontinence

GTx, Inc. (Nasdaq: GTXI) today announced top-line clinical trial results demonstrating that a daily dose of enobosarm 3 mg (GTx-024) substantially improved stress urinary incontinence (SUI) in women, as well as related...

GTx Provides Corporate Update And Reports Second Quarter 2017 Financial Results

GTx Provides Corporate Update And Reports Second Quarter 2017 Financial Results

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the second quarter of 2017 and highlighted recent accomplishments and upcoming milestones.

GTx Announces Positive Preliminary Results From Ongoing Phase 2 Proof-of-Concept Clinical Trial In Women With Stress Urinary Incontinence

GTx, Inc. (Nasdaq: GTXI) today announced release of preliminary clinical data from its ongoing, open-label, Phase 2 clinical trial of enobosarm 3 mg (GTx-024) in postmenopausal women with stress urinary incontinence (SUI).

GTx Provides Corporate Update And Reports First Quarter 2017 Financial Results

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the first quarter of 2017, and highlighted recent accomplishments and upcoming milestones.

GTx Announces Acceptance Of An Abstract On Preliminary Results From Phase 2 Clinical Trial In Women With Stress Urinary Incontinence At The International Continence Society Annual Meeting

GTx, Inc. (Nasdaq: GTXI) today announced the acceptance of an abstract on preliminary clinical data from its ongoing, open-label, Phase 2 proof-of-concept clinical trial of enobosarm (GTx-024) evaluating enobosarm 3 mg in...

GTx Announces Results From Preclinical Studies Of SARMs In Duchenne Muscular Dystrophy Models Published In Human Molecular Genetics

GTx, Inc. (Nasdaq: GTXI) today announced the publication in the journal Human Molecular Genetics of results from preclinical studies supporting the potential efficacy of the Company's SARMs, and in particular GTx-026, for...